An analysis of 353 breast cancer patients and a public data set showed that the high CD47 mRNA levels were correlated with poor-prognosis molecular subtypes (basal, Her2/Neu+) and adverse clinicopathological parameters (high-grade, ER-, PR-). Here, ERBB2 is linked to breast cancer.